NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM
申请人:Boyd Robert
公开号:US20110092541A1
公开(公告)日:2011-04-21
The present invention provides novel compounds as well as compositions and methods using the same for preventing and/or treating degenerative disorders of the central nervous system. In particular, the present invention provides methods for preventing and/or treating Parkinson's disease.
Method for Treating Alzheimer's Disease Using Pharmacological Chaperones To Increase The Activity of Gangliosidases
申请人:Wustman Brandon
公开号:US20120309788A1
公开(公告)日:2012-12-06
The present invention relates to a method for treating an individual having Alzheimer's Disease by using pharmacological chaperones to increase the activity of gangliosidase and/or sialidase enzymes involved in ganglioside catabolism.
Novel Compositions for Preventing and/or Treating Degenerative Disorders of the Central Nervous System
申请人:AMICUS THERAPEUTICS, INC.
公开号:US20140080871A1
公开(公告)日:2014-03-20
The present invention provides novel compounds as well as compositions and methods using the same for preventing and/or treating degenerative disorders of the central nervous system. In particular, the present invention provides methods for preventing and/or treating Parkinson's disease.
Novel Compositions for Preventing and/or Treating Lysosomal Storage Disorders
申请人:Amicus Therapeutics, Inc.
公开号:US20140086896A1
公开(公告)日:2014-03-27
The present invention provides novel compositions as well as methods for preventing and/or treating lysosomal storage disorders. In particular, the present invention provides methods for preventing and/or treating Gaucher's disease.
Method for Treating Cerebral Amyloid Angiopathy Using Pharmacological Chaperones to Increase the Activity of Gangliosidases
申请人:Amicus Therapeutics, Inc.
公开号:US20150374733A1
公开(公告)日:2015-12-31
The present invention relates to a method for treating an individual having Cerebral Amyloid Angiopathy by using pharmacological chaperones to increase the activity of gangliosidase and/or sialidase enzymes involved in ganglioside catabolism.